ATE386812T1 - Methode für die produktion von multivalenten influenza hämagglutinin vakzinen - Google Patents

Methode für die produktion von multivalenten influenza hämagglutinin vakzinen

Info

Publication number
ATE386812T1
ATE386812T1 AT02076629T AT02076629T ATE386812T1 AT E386812 T1 ATE386812 T1 AT E386812T1 AT 02076629 T AT02076629 T AT 02076629T AT 02076629 T AT02076629 T AT 02076629T AT E386812 T1 ATE386812 T1 AT E386812T1
Authority
AT
Austria
Prior art keywords
recombinant
purification
cloned
signal peptide
insect cells
Prior art date
Application number
AT02076629T
Other languages
English (en)
Inventor
Gale Eugene Smith
Franklin Volvovitz
Bethanie E Wilkinson
Andrei I Voznesensky
Craig Stanway Hackett
Original Assignee
Mg Pmc Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mg Pmc Llc filed Critical Mg Pmc Llc
Priority claimed from EP95922133A external-priority patent/EP0833933B1/de
Application granted granted Critical
Publication of ATE386812T1 publication Critical patent/ATE386812T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT02076629T 1995-05-26 1995-05-26 Methode für die produktion von multivalenten influenza hämagglutinin vakzinen ATE386812T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95922133A EP0833933B1 (de) 1993-09-13 1995-05-26 Vektor und methode zur herstellung von influenza hämagglutinin
EP02076629A EP1275726B1 (de) 1995-05-26 1995-05-26 Methode für die Produktion von multivalenten Influenza Hämagglutinin Vakzinen

Publications (1)

Publication Number Publication Date
ATE386812T1 true ATE386812T1 (de) 2008-03-15

Family

ID=39469766

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02076629T ATE386812T1 (de) 1995-05-26 1995-05-26 Methode für die produktion von multivalenten influenza hämagglutinin vakzinen

Country Status (6)

Country Link
EP (1) EP1275726B1 (de)
AT (1) ATE386812T1 (de)
DE (1) DE69535716T2 (de)
ES (1) ES2300419T3 (de)
HK (1) HK1054050B (de)
PT (1) PT1275726E (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1982727A1 (de) * 2007-04-17 2008-10-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Reinigung von viralen Proteinen
CN118978590B (zh) * 2024-10-12 2025-01-21 北京溯本源和生物科技有限公司 一种利用重组流感病毒免疫小鼠制备杂交瘤单抗的方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106185D0 (en) * 1991-03-22 1991-05-08 Wellcome Found Biological control agents
IL103928A0 (en) * 1991-12-11 1993-04-04 American Home Prod Expression of specific immunogens using viral antigens
AU2517995A (en) * 1994-05-20 1995-12-18 Microgenesys, Inc. Immunogenic carcinoembryonic antigen and methods of use and production

Also Published As

Publication number Publication date
EP1275726A3 (de) 2003-02-26
ES2300419T3 (es) 2008-06-16
HK1054050B (en) 2008-09-26
PT1275726E (pt) 2008-05-16
EP1275726B1 (de) 2008-02-20
EP1275726A2 (de) 2003-01-15
DE69535716D1 (de) 2008-04-03
HK1054050A1 (en) 2003-11-14
DE69535716T2 (de) 2009-03-19

Similar Documents

Publication Publication Date Title
NZ288026A (en) A method for producing influenza hemagglutinin multivalent vaccines
DE69535940D1 (de) Verfahren zur Herstellung von biologischen Produkten in Protein-freiem Kultur
US5753489A (en) Method for producing viruses and vaccines in serum-free culture
FI932678A7 (fi) Alfaviruksiin perustuvia DNA-ilmentämissysteemejä
GEP20084431B (en) Papilloma virus vaccine
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
CA2220133A1 (en) Recombinant vesiculoviruses and their uses
NO874750L (no) Bestemte dna-sekvenser avledet fra et papillomavirusgenom, deres bruk i in vitro diagnostikk og produksjon av antigene preparater.
DE69535018D1 (de) Papillomavirus vakzine
DE69838383D1 (de) Kulturmedium mit sojabohnenextrakt als aminosäuren-quelle und ohne proteinkomplexe tierischen ursprungs
ATE159170T1 (de) Impfstoffe und diagnosetest für haemophilus influenzae
DE69535716D1 (de) Methode für die Produktion von multivalenten Influenza Hämagglutinin Vakzinen
DE68923286D1 (de) Impfstoffe und testsätze für haemophilus influenzae.
ATE424409T1 (de) Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel
EP2374894A3 (de) Verfahren zum Herstellen von hämaglutinin-multivalenten Influenza-Impfstoffen
KR880000579A (ko) 베리셀라-죠스터 바이러스의 생산방법
DE3776034D1 (de) Vakzine.
ATE206762T1 (de) Rekombinante viren, enthaltend eine künstliche proteolytische schnittstelle.
KR960041360A (ko) 돼지파보바이러스의 vp2 단백질의 대량 생산방법 및 돼지파보바이러스 감염증용 백신의 제조방법
KR960023065A (ko) B형 간염 바이러스 표면항원과 C형 간염 바이러스 초변화 영역 단백질의 융합 단백질인 preS2HV 및 그의 제조 방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1275726

Country of ref document: EP